许国生,车鹏,胡俊,黄可,黎林果,汤道雄.氨磺必利和利培酮治疗老年精神分裂症的效果和安全性Meta分析[J].四川精神卫生杂志,2020,33(4):342-348.Xu Guosheng,Che Peng,Hu Jun,Huang Ke,Li Linguo,Tang Daoxiong,Efficacy and safety of amisulpride and risperidone in the treatment of senile schizophrenia:a Meta-analysis[J].SICHUAN MENTAL HEALTH,2020,33(4):342-348
氨磺必利和利培酮治疗老年精神分裂症的效果和安全性Meta分析
Efficacy and safety of amisulpride and risperidone in the treatment of senile schizophrenia:a Meta-analysis
投稿时间:2020-03-19  
DOI:10.11886/scjsws20200319001
中文关键词:  氨磺必利  利培酮  老年  精神分裂症  Meta分析
英文关键词:Amisulpride  Risperidone  Senile  Schizophrenia  Meta-analysis
基金项目:
作者单位邮编
许国生 四川省精神卫生中心·绵阳市第三人民医院四川 绵阳 621000 621000
车鹏 四川省精神卫生中心·绵阳市第三人民医院四川 绵阳 621000 621000
胡俊 四川省精神卫生中心·绵阳市第三人民医院四川 绵阳 621000 621000
黄可 四川省精神卫生中心·绵阳市第三人民医院四川 绵阳 621000 621000
黎林果 四川省精神卫生中心·绵阳市第三人民医院四川 绵阳 621000 621000
汤道雄 四川省精神卫生中心·绵阳市第三人民医院四川 绵阳 621000 621000
摘要点击次数:
全文下载次数:
中文摘要:
      目的 系统评价氨磺必利和利培酮治疗老年精神分裂症的效果和安全性,为老年精神分裂症患者药物治疗的选择提供参考。方法 检索PubMed、Cochrane Library、Embase、中国知网、万方数据库、维普数据库,纳入关于氨磺必利和利培酮治疗老年精神分裂症效果和安全性的随机对照试验(RCT)。由两名评价员独立评价文献质量和提取数据,采用RevMan 5.3进行Meta分析。结果 共纳入7篇RCT,Meta分析结果显示:①老年精神分裂症患者使用氨磺必利和利培酮治疗后2周、4周、6周、8周的PANSS总评分比较差异无统计学意义(P>0.05);②老年精神分裂症患者使用氨磺必利与利培酮治疗后4周、8周阴性症状评分差异无统计学意义(P>0.05);③老年精神分裂症患者使用氨磺必利与利培酮治疗后4周、8周阳性症状评分差异无统计学意义(P>0.05);④氨磺必利组和利培酮组失眠、心动过速、震颤、头晕、头痛、静坐不能、肌肉强直、胃肠反应比较差异均无统计学意义(P>0.05)。结论 氨磺必利和利培酮在治疗老年精神分裂症的效果和安全性相当。
英文摘要:
      Objective To systematically evaluate the efficacy and safety of amisulpride and risperidone in the treatment of senile schizophrenia, and to provide reference for the selection of drug.Methods All literature were searched in PubMed, Cochrane Library, Embase, CNKI, Wanfang database and Weipu database . The randomized controlled trials (RCT) on the efficacy and safety of amisulpride and risperidone in the treatment of senile schizophrenia were included. Two reviewers evaluated the quality of the literature and extracted data independently, then used RevMan 5.3 for Meta-analysis.Results A total of 7 RCTs were included. Meta-analysis results showed as below: ① There was no statistically significant difference in the total PANSS scores of 2 weeks, 4 weeks, 6 weeks, and 8 weeks after treatment with amisulpride and risperidone in senile patients with schizophrenia (P>0.05). ② There was no statistically significant difference in the negative symptom scores of 4 and 8 weeks after treatment with amisulpride and risperidone in senile schizophrenia (P>0.05). ③ There was no statistically significant difference in the positive symptom scores of 4 and 8 weeks after treatment with amisulpride and risperidone in senile schizophrenia (P>0.05). ④ No difference was found in the occurrenct of insomnia, tachycardia, tremor, dizziness, headache, akathisia, muscle rigidity and gastrointestinal reactions in the two groups(P>0.05).Conclusion Amisulpride and risperidone have equivalent efficacy and safety in the treatment of senile schizophrenia.
查看全文  查看/发表评论  下载PDF阅读器
关闭